

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/825,381	04/15/2004	G. Ian Rowlandson	146461 (5024-00123)	8457
7590 07/07/2006			EXAMINER	
Joseph D. Kuborn			LAYNO, CARL HERNANDZ	
Andrus, Sceales, Starke & Sawall, LLP Suite 1100			ART UNIT	PAPER NUMBER
100 East Wisconsin Avenue Milwaukee, WI 53202-4178			3766	
			DATE MAILED: 07/07/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05) Application/Control Number: 10/825,381 Page 2

Art Unit: 3766

DETAILED ACTION

Information Disclosure Statement

1. Acknowledgment is made of applicant's Information Disclosure Statement (PTO-1449), which was received by the Office on April 15, 2004 and May 26, 2004.

Drawings

2. Applicant's formal drawings were received by the Office on April15, 2004 and have been approved by the Examiner.

Specification

3. Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

In this case, applicant should refrain from using the language "the invention" in line 2 of the Abstract.

Claim Rejections - 35 USC § 102

Application/Control Number: 10/825,381 Page 3

Art Unit: 3766

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1, 3, and 8-10 are rejected under 35 U.S.C. 102(b) as being anticipated by the Tateishi et al article "Observation of sleep-related breathing disorders in patients with coronary artery disease by ambulatory electrocardiogram-respiration monitoring system" (Jpn Circ J, 1994 Nov; 58(11):831-835).

The Tateishi et al article "Observation of sleep-related breathing disorders in patients with coronary artery disease by ambulatory electrocardiogram-respiration monitoring system" (Jpn Circ J, 1994 Nov; 58(11):831-835) describes a study whose conduct appears to read upon the method steps claimed by the applicant. Specifically, the abstract describes a study involving 85 coronary artery patients who were examined using ambulatory electrocardiogram-respiration monitoring systems (AERMS) in which both respiratory sensors and ECG sensors were attached to the patients. Data from these sensors were used to diagnose 9 patients with sleep-related breathing disorders (SRBDs) (i.e. patients suffering more than 30 Apneic episodes during a sleeping period). Follow up studies were conducted on these patients including occurrence of "sudden death, myocardial infarction, and ventricular tachyarrhythmia". Following a period of about 18 months, it was statistically shown that 44% of patients in the SRBD group experienced cardiac events compared to 6% of the non-SRBD patients.

In regard to claims 3, 8, and 9, the Tateishi et al equipment monitors/calculates ejection fraction (EF) and can determine when EF<50% (Abstract, line 9). In addition, the respiratory sensor is strapped to "the right upper abdominal wall" to sense motions (Abstract, line 3).

In regard to claim 10, patients were diagnosed as having sleep-related breathing disorders (SRBDs) if they suffered more than 30 Apneic episodes during a sleeping period (each apneic episode corresponding to a lack of respiratory wall movement for a period of at least 10 seconds) (Abstract, lines 4-5).

Allowable Subject Matter

- 6. Claims 2, 4-7, and 11-13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 7. Claims 14-28 are allowed.
- 8. The following is a statement of reasons for the indication of allowable subject matter:

 Independent claims 14, 22, 27, and 28 describe a computer program and corresponding device claims, respectively, involving a device for monitoring sleep apnea and a risk of sudden cardiac death. Unlike the AERMS device described by the Tateishi et al article (cited supra), the applicant's device includes an integrated "patient data acquisition system" or "means" for determining a "correlation between sleep apnea and a risk of sudden cardiac death". Whereas, the Tateishi et al article appears to calculate this relationship by hand after a long observation

Application/Control Number: 10/825,381 Page 5

Art Unit: 3766

period. Consequently, the Examiner deems these claims and their depending claims to be allowable.

Conclusion

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

The Forbes (US 5,187,657) patent describes a device capable of monitoring ECG and respiration data for determining a patient's susceptibility to sudden cardiac death (Abstract, line 18) and to sleep apnea (col.7, lines 50-52). Unlike applicant's device, that of Forbes does not attempt to define the relationship between sleep apnea and sudden cardiac death.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carl H. Layno whose telephone number is (571) 272-4949. The examiner can normally be reached on 9/4/5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert E. Pezzuto can be reached on (571) 272-6996. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/825,381

Art Unit: 3766

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

Page 6

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CARL LAYNO

PRIMARY EXAMINER

Carl H. Layro

CHL

6/30/2006